Wungki Park, MD MS

Important work showing efficacy of daraxonrasib in patients with pancreas cancer. Looking forward to data for patients with NSCLC. Pancreas cancer work in @NEJM from @CentralParkWMD @MSKCancerCenter as well as @bherzbergmd https://t.co/5id3Njyhv4 https://t.co/cYJZs0s29x

1/n Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM A novel💡 way to shut down ⚔️RAS, one of the most important oncogenic drivers in cancer that had long been considered “undruggable.” 🔗https://t.co/ptfNVcxrb4 Shout out to Brian Wolpin, @CentralParkWMD @GarridoLagunaMD @AlexSpiraMDPhD @salmanpunekar @MeredithPelster @bherzbergmd Nilo Azad Aparna Hegde @DavidHongMD and the whole team who dedicated to this study. @EileenMOReilly #HBP #HumansBeyondPatients

Thank you @wolfblitzer and @CNN for highlighting this milestone for #PancreaticCancer 💜 For more than four years I’ve had the privilege of helping develop daraxonrasib clinically and leading translational research while caring for patients with previously treated advanced disease. Some have had exceptional responses lasting years. Children’s weddings. Grandchildren’s graduations. Long-planned travels. Seeing these moments become possible has been a true joy in my clinic. That is what more time means. Now I lead MSK’s participation in RASolute-303 to test daraxonrasib as initial treatment for metastatic disease. Across the field we are also developing next-generation RAS inhibitors and degraders and testing novel combinations and treatment in earlier-stage disease. Our goal is to make this benefit deeper and longer-lasting for our patients. Grateful to fellow investigators including @EileenMOReilly and all the international investigators, our clinical and research teams and above all our courageous patients and families. This is why we do this work. And this is just the beginning. @CpcrMsk @MSK_DeptOfMed @RevMedicines @PanCAN @OncBrothers @OncoAlert @oncodaily @OncoDailyGI @lustgartenfdn

Ready. One of my favorite moments before an oral presentation at a big stage is walking into an empty auditorium and breathing the air of this room. Soon it will be filled with colleagues from around the world, all united by one goal - improving outcomes for patients with GI cancers. Honored to share our work #CLDN18 #GLEAM at #ESMOGI26. Looking forward to the discussions ahead. #Science We advance because we learn from negative result. #GRIT #proffered #abstract #GIOncology #PancreaticCancer #KRAS #TranslationalResearch @CpcrMsk @MSK_DeptOfMed @MSKCancerCenter @PanCAN @letswinpc @Pankind_Aus

A major impact! Thanks to all the coauthors, clinical research team and our courageous patients who dedicated their time and more at the plenary #ASCO26 @ASCO @ASCOPost 💜 https://t.co/BOSuhn2xCa

Thrilled 🤩 to join this 🔋Powerhouse session at #ESMOGI2026. Incredible to witness so many advances in pancreatic cancer presented on one stage and to share it with leaders including Brian Wolpin, Nilo Azad, Eric Van Cutsem and @MacarullaTeresa The era of K/RAS inhibitors, rational combinations and biomarker-driven therapeutics is here. #daraxonrasib #zoldonrasib Unprecedented response rates in this disease ever! We keep learning from the positive and negative work. Search and REsearch! I really appreciate the team so dedicated to learn the science from the #GLEAM trial #CLDN18 #zolbetuximab We’re finally moving the field forward. The future of pancreatic cancer has never looked brighter 💡 #PancreaticCancer #KRAS #RAS #TeamScience @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @PanCAN @letswinpc @Pankind_Aus @OncoAlert @OncBrothers @oncodaily @OncoDailyGI @NatPancFdn